Pharmafile Logo
Pharmafocus logo
Advanced Search

National Institute for Health and Care Excellence

Showing 5 posts of 5 posts found.

Astra Zeneca Logo

NICE recommends Benralizumab for Rare Form of Vasculitis

August 15, 2025
Medical Communications, Research and Development AstraZeneca, Immunology, National Institute for Health and Care Excellence, vasculitis

The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as an add-on treatment for adult …

News
640px-eye_iris

NICE recommends treatment for rare genetic eye disorder

August 11, 2025
Medical Communications Chiesi, Leber Hereditary Optic Neuropathy, NHS England, National Institute for Health and Care Excellence, Opthalmology, Rare Diseases

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Cheisi’s idebenone (Raxone) within its …

News

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer

July 30, 2025
Medical Communications, Research and Development AstraZeneca, NHS, National Institute for Health and Care Excellence, Oncology, dual immunotherapy, hepatocellular carcinoma, liver cancer

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its dual immunotherapy …

News

NICE recommends spevigo for rare and severe psoriasis flares

June 20, 2025
Medical Communications, Research and Development Dermatology, NHS, National Institute for Health and Care Excellence, generalised pustular psoriasis

The National Institute for Health and Care Excellence (NICE) has recommended Spevigo (spesolimab) for the treatment of generalised pustular psoriasis …

News

NICE recommends treatment for chronic kidney disease, IgA nephropathy

May 23, 2025
Market & Product Development, Medical Communications, Research and Development IgA nephropathy, National Institute for Health and Care Excellence, Nephrology, kidney disease

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Vifor’s FILSPARI (sparsentan) for …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025